Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

被引：42

作者：

Peters, Solange ^{[1
]}

Cappuzzo, Frederico ^{[2
]}

Horn, Leora ^{[3
]}

Paz-Ares, Luis ^{[4
]}

Borghaei, Hossein ^{[5
]}

Barlesi, Fabrice ^{[6
]}

Steins, Martin ^{[7
]}

Felip, Enriqueta ^{[8
]}

Spigel, David ^{[9
]}

Dorange, Cecile ^{[10
]}

Lu, Haolan ^{[10
]}

Healey, Diane ^{[10
]}

Sanchez, Teresa Kong ^{[10
]}

Bhagavatheeswaran, Prabhu ^{[10
]}

Novotny, James, Jr. ^{[10
]}

Lestini, Brian ^{[10
]}

Brahmer, Julie ^{[11
]}

机构：

[1] Univ Lausanne, Lausanne, Switzerland

[2] Osped Santa Maria Croci, Ausl Romagna, Dept Oncol & Hematol, Ravenna, Italy

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Hosp Univ Doce Octubre & Cnio, Madrid, Spain

[5] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[6] Aix Marseille Univ, AP HM, Marseille, France

[7] Thoraxklin Heidelberg GmbH, Heidelberg, Germany

[8] Hosp Univ Vall DHebron, Barcelona, Spain

[9] Sarah Cannon Res Inst Tennessee Oncol PLCC, Thorac Oncol, Nashville, TN USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA

来源：

关键词：

Nivolumab; non-squamous NSCLC; overall survival; baseline characteristics;

D O I：

10.1016/j.jtho.2016.11.241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA03.05

引用

页码：S253 / S253

页数：1